Investment Highlights

• Enormous market

  Urbanization changes our lifestyles. With the size of the aging population growing, there will be more diabetics in China. As the patients get greater consumption power, the medical insurance system improves, and more innovative drugs for diabetes are developed, the diabetes drug market in China will be worth RMB 259.2 billion yuan by 2030.

  
  

  
• Huge growth room

  The Chinese drug market for diabetes is dominated by traditional drugs. In 2018, the sales of GLP-1 drugs under this project were only RMB 700 million yuan, accounting for only 1.2%. The number during the same period in the United States was USD 5.6 billion, accounting for 15.5%. This suggests that there is huge growth room for GLP-1 drugs.

  
• Low production costs

  E2HSA is a long-acting drug with a long administration period. It needs to be administered once a week, with small dosage but high efficiency. The core yeast fermentation preparation process is cost-effective

  Gene transfer         >>         Yeast expression          >>        Macromolecular protein production

• Diverse product pipelines

  The pipeline products include E2HSA and other approved type 2 diabetes treatment combination drugs, weight management drugs, interleukin-2 fusion protein tumor treatment adjuvant drugs.

  
  

  Product	Use	Preclinical research, clinical phase I, clinical phase II, clinical phase III	Estimated completion date for the current phase
  E2HSA	Type 2 diabetes injection, GLP-1 weekly preparation, minimal hypoglycemia		December 2021
  E2HSA+Metformin	To treat type 2 diabetes, in combination with metformin		December 2024
  Interleukin-2 fusion protein	Adjuvant drugs for cancer treatment		Second half of 2022